Ironwood Pharmaceuticals (IRWD) News Today → A once-in-a-century investment opportunity (From Stansberry Research) (Ad) Free IRWD Stock Alerts $5.88 -0.07 (-1.18%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 1:48 AM | americanbankingnews.comQ1 2025 Earnings Estimate for Ironwood Pharmaceuticals, Inc. Issued By Zacks Research (NASDAQ:IRWD)May 27 at 1:56 AM | marketbeat.comQ1 2025 Earnings Estimate for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Issued By Zacks ResearchIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Research analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for Ironwood Pharmaceuticals in a report issued on Friday, May 24th. Zacks Research analyst R. Department now expects that the biotechnology companyMay 26 at 3:36 AM | americanbankingnews.comIronwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 3%May 25, 2024 | americanbankingnews.comFY2024 EPS Estimates for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Cut by Zacks ResearchMay 24, 2024 | marketbeat.comZacks Research Analysts Lower Earnings Estimates for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Zacks Research cut their FY2024 earnings estimates for shares of Ironwood Pharmaceuticals in a research report issued on Wednesday, May 22nd. Zacks Research analyst R. Department now expects that the biotechnologMay 23, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Hits New 52-Week Low at $6.20Ironwood Pharmaceuticals (NASDAQ:IRWD) Reaches New 12-Month Low at $6.20May 23, 2024 | americanbankingnews.comIronwood Pharmaceuticals, Inc. to Post Q2 2024 Earnings of $0.18 Per Share, Zacks Research Forecasts (NASDAQ:IRWD)May 23, 2024 | marketbeat.comAnalysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research reduced their Q2 2024 earnings estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 22nd. Zacks Research analyst R. Department now expects thMay 22, 2024 | markets.businessinsider.comIronwood Pharma’s Apraglutide Poised for Blockbuster Status with Strong Phase 3 Results: A Buy RatingMay 21, 2024 | markets.businessinsider.comIronwood Pharmaceuticals’ Growth Potential Bolstered by Promising LINZESS and Apraglutide Clinical DataMay 21, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Trading 3.3% Higher Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Up 3.3%May 21, 2024 | finance.yahoo.comIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)May 21, 2024 | marketbeat.comHillsdale Investment Management Inc. Makes New Investment in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Hillsdale Investment Management Inc. purchased a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 157,400 shares of the biotechnology companMay 21, 2024 | americanbankingnews.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Buy" from AnalystsMay 19, 2024 | marketbeat.comBNP Paribas Financial Markets Has $6.56 Million Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)BNP Paribas Financial Markets increased its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 35.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 572,947 shares of the biotechnology comMay 14, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 2.4%Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 2.4%May 14, 2024 | msn.comIronwood Pharmaceuticals’ (NASDAQ:IRWD) Challenges Continue with Q1 MissesMay 12, 2024 | finance.yahoo.comUS$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest ResultsMay 11, 2024 | morningstar.comIronwood Pharmaceuticals Inc Class AMay 10, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results, Misses Expectations By $0.20 EPSIronwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.20). The company had revenue of $74.90 million during the quarter, compared to the consensus estimate of $105.75 million. Ironwood Pharmaceuticals had a negative net margin of 226.37% and a negative return on equity of 185.45%. The firm's revenue was down 28.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.25 earnings per share.May 10, 2024 | finance.yahoo.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comIronwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical AdvancementsMay 10, 2024 | marketbeat.comCraig Hallum Cuts Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target to $14.00Craig Hallum reduced their target price on shares of Ironwood Pharmaceuticals from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Friday.May 10, 2024 | markets.businessinsider.comIronwood Pharma’s Strong Commercial Execution and Promising Pipeline Support Buy RatingMay 9, 2024 | seekingalpha.comIronwood Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down to $8.12Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down to $8.12May 9, 2024 | investorplace.comIRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comIronwood Pharmaceuticals Non-GAAP EPS of -$0.02 misses by $0.17, revenue of $74.88M misses by $30.82MMay 9, 2024 | finance.yahoo.comIronwood Pharmaceuticals Reports First Quarter 2024 ResultsMay 6, 2024 | businesswire.comIronwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences ConferenceMay 6, 2024 | marketbeat.comVictory Capital Management Inc. Lowers Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Victory Capital Management Inc. lowered its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 4.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,224,583 shares ofMay 5, 2024 | marketbeat.comLSV Asset Management Lowers Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)LSV Asset Management lessened its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 5.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,782,101 shares of the biotechnology company's stock after selling 382,108 shaMay 3, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Expected to Earn FY2025 Earnings of $0.88 Per ShareIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Research analysts at Capital One Financial boosted their FY2025 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research report issued on Wednesday, May 1st. Capital One Financial analyst T. Chiang now forMay 1, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Trading 5.5% Higher Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Up 5.5%May 1, 2024 | businesswire.comIronwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024April 30, 2024 | investorplace.comStock Market Crash Warning: Don't Get Caught Holding These 3 Biotech StocksApril 25, 2024 | businesswire.comIronwood Pharmaceuticals to Host First Quarter 2024 Investor Update CallApril 22, 2024 | insidermonkey.com5 Best Low Price Pharma Stocks To Invest InApril 20, 2024 | nasdaq.comGuru Fundamental Report for IRWDApril 15, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Reaches New 52-Week Low at $7.78Ironwood Pharmaceuticals (NASDAQ:IRWD) Sets New 1-Year Low at $7.78April 14, 2024 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest UpdateIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 21,950,000 shares, a growth of 16.9% from the March 15th total of 18,770,000 shares. Approximately 14.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 4,770,000 shares, the days-to-cover ratio is presently 4.6 days.April 8, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 2.9%Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 2.9%April 3, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Sets New 52-Week Low at $8.07Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month Low at $8.07April 1, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Ironwood Pharma (IRWD)March 29, 2024 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Upgraded to "Buy" by StockNews.comStockNews.com raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday.March 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)March 28, 2024 | businesswire.comIronwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)March 22, 2024 | marketbeat.comEquities Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Zacks Research lifted their FY2024 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, March 20th. Zacks Research analyst R. Department now forecasts that the bMarch 21, 2024 | marketbeat.comResearch Analysts Offer Predictions for Ironwood Pharmaceuticals, Inc.'s Q4 2024 Earnings (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research lifted their Q4 2024 earnings estimates for shares of Ironwood Pharmaceuticals in a research report issued on Wednesday, March 20th. Zacks Research analyst R. Department now forecasts that the bioteMarch 20, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - IRWD Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now IRWD Media Mentions By Week IRWD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IRWD News Sentiment▼0.150.82▲Average Medical News Sentiment IRWD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IRWD Articles This Week▼203▲IRWD Articles Average Week Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Innoviva News OPKO Health News MannKind News Dynavax Technologies News Cryoport News Ligand Pharmaceuticals News IGM Biosciences News Kura Oncology News Lexicon Pharmaceuticals News Verastem News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IRWD) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
